RECAP 2 裸盖菇素的行为影响
经验、意识意识和可塑性在裸盖菇素行为影响中的作用 - 后续研究(RECAP 2 研究)
The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.
Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing.
Participants will:
- Receive one of four possible combinations of medications
- Undergo an MRI
- Complete questionnaires
- Undergo transcranial magnetic stimulation (TMS) and EEG
- Volunteer for an open-label follow-up phase of study
研究概览
详细说明
The purpose of this study is to investigate the role that inducing neuroplasticity plays in the behavioral effects of psilocybin in people with modest decrements in emotional wellbeing.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:RECAP Study Contact
- 电话号码:608-263-4852
- 邮箱:recap2@psychiatry.wisc.edu
学习地点
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- 招聘中
- UW School of Medicine and Public Health
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 18 to 65 years at screening, of any identified gender and racial/ethnic group
- Physically healthy; does not meet criteria for an exclusionary medical condition
- English-speaking (able to provide consent and complete questionnaires)
- Modest decrement in self-reported wellbeing without the presence of a DSM-5 Axis I mood or anxiety disorder
- Able to undergo magnetic resonance imaging (MRI) and transcranial magnetic stimulation (TMS)
Exclusion Criteria:
- Exclusionary DSM-5 psychiatric diagnosis and/or active suicidal ideation
- Exclusionary medical conditions
- Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)
- Clinically significant electrocardiogram (ECG)
- Use of psychotropic or CNS-altering medications within 3 months of screening
- Hypertension or tachycardia
Participants invited to participate in the 28-day open label follow-up phase will:
-
Fully complete all activities associated with the randomized phase, including the virtual Day 84 assessment, before being approached about participation in the open label phase.
-
Participants who meet stopping criteria during the randomized phase are not eligible to enroll in the open label phase.
-
Participants who withdraw from the randomized phase are not eligible to enroll in the open label phase.
-
Enrollment into the open label phase must occur in the following sequence:
- participants who have fully completed the randomized phase are screened for eligibility;
- eligible participants meet with the study team and provide informed consent for the open label phase;
- baseline eligibility is reassessed to confirm that participation in the open label phase remains appropriate and safe.
The Principal Investigator may decline or defer open-label enrollment when unresolved concerns make participation unsafe or scientifically inappropriate.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Group 1: Psilocybin and intravenous (IV) midazolam
Psilocybin (25 mg) + IV midazolam |
25mg of psilocybin
其他名称:
1mg of psilocybin
其他名称:
The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session. |
|
实验性的:Group 2: Psilocybin and IV saline
Psilocybin (25 mg) + IV saline (placebo for midazolam) |
25mg of psilocybin
其他名称:
1mg of psilocybin
其他名称:
Saline will be administered as a placebo for midazolam |
|
实验性的:Group 3: Psilocybin and IV midazolam
Psilocybin (1 mg/control) + IV midazolam |
25mg of psilocybin
其他名称:
1mg of psilocybin
其他名称:
The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session. |
|
实验性的:Group 4: Psilocybin and IV saline
Psilocybin (1 mg/control) + IV saline |
25mg of psilocybin
其他名称:
1mg of psilocybin
其他名称:
Saline will be administered as a placebo for midazolam |
|
实验性的:Exploratory Open Label Follow-Up Phase
Psilocybin (25 mg) |
25mg of psilocybin
其他名称:
1mg of psilocybin
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Warwick-Edinburgh Mental wellbeing Scale (WEMWBS)
大体时间:Baseline to 7 days post-dose
|
WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing. |
Baseline to 7 days post-dose
|
|
Change in Brief Experiential Avoidance Questionnaire (BEAQ)
大体时间:Baseline to 7 days post-dose
|
The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance |
Baseline to 7 days post-dose
|
|
Change in Probabilistic Reversal Learning (PRL)
大体时间:Baseline to 7 days post-dose
|
Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift). |
Baseline to 7 days post-dose
|
|
Change in transcranial magnetic stimulation evoked potential (TEP) amplitude
大体时间:Baseline to 7 days post-dose
|
TEP measures neural excitability in the stimulated region of the brain. |
Baseline to 7 days post-dose
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in WEMWBS
大体时间:Baseline to 28 days post-dose
|
WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing. |
Baseline to 28 days post-dose
|
|
Change in BEAQ
大体时间:Baseline to 28 days post-dose
|
The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance |
Baseline to 28 days post-dose
|
|
Change in PRL
大体时间:Baseline to 28 days post-dose
|
Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift). |
Baseline to 28 days post-dose
|
|
Change in TEP amplitude
大体时间:Baseline to 28 days post-dose
|
TEP measures neural excitability in the stimulated region of the brain. |
Baseline to 28 days post-dose
|
|
Altered States of Consciousness (ASC) questionnaire
大体时间:Dosing 1 day
|
Participants will complete a selection of several questions from the ASC questionnaire that strongly associate positively or negatively with later antidepressant effect of psilocybin in patients with treatment resistant depression or capture classic features of the psychedelic experience. During the dosing session, investigator will repeatedly ask selected items from the ASC scale to get a "real time" measure of what the participants are experiencing. Each of these items will be scored separately. Higher score are indicative of a more intense psychedelic experience. |
Dosing 1 day
|
|
Emotional Breakthrough Inventory (EBI)
大体时间:Dosing 1 day
|
The EBI is a 6-item scale that assesses the presence and severity of emotionally challenging/distressing experiences that occur during a psychedelic experience. Participants rate to what extent the statements apply to their experience by marking a single line across each scale. Scale ranges from not at all to very much so. Higher scores (more slashes toward the 'very much so' end) on the scale have been associated with enhanced well-being following psychedelic use |
Dosing 1 day
|
|
Psychological Insight Questionnaire (PIQ)
大体时间:Dosing 1 day
|
The PIQ is a 23-item instrument designed to query self-perceived attainment of insight during a psychedelic medicine session. Items are rated on a 6-point Likert scale, 0 = no not at all and 5 = extremely. Possible scares range from 0-115, with higher scores indicating greater insight. |
Dosing 1 day
|
合作者和调查者
合作者
调查人员
- 首席研究员:Charles Raison, MD、University of Wisconsin, Madison
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 2024-0852
- A538900 (其他标识符:UW- Madison)
- SMPH/PSYCHIATRY/PSYCHIATRY (其他标识符:UW- Madison)
- Protocol Version 9/30/2026 (其他标识符:UW- Madison)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.